FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2475385134> ?p ?o ?g. }

• W2475385134 endingPage "e567" @default.
• W2475385134 startingPage "e559" @default.
• W2475385134 abstract "BackgroundDespite the introduction of immunisation for hepatitis B virus (HBV) in the 1990s, HBV-related morbidity and mortality remain high in sub-Saharan Africa. Identification and treatment of asymptomatic people with chronic HBV infection should reduce the disease burden. We therefore assessed the feasibility of a screen-and-treat programme for HBV infection in The Gambia, west Africa, and estimated the proportion of HBV-infected people who had significant liver disease in need of treatment.MethodsBetween Dec 7, 2011, and Jan 24, 2014, individuals living in randomly selected communities in western Gambia were offered hepatitis B surface antigen (HBsAg) screening via a point-of-care test. The test was also offered to potential blood donors attending the central hospital in the capital, Banjul. HBsAg-positive individuals were invited for a comprehensive liver assessment and were offered treatment according to international guidelines. We defined linkage to care as visiting the liver clinic at least once. Eligibility for treatment was judged in accordance with the 2012 European Association for the Study of the Liver guidelines.FindingsHBsAg screening was accepted by 5980 (weighted estimate 68·9%, 95% CI 65·0–72·4) of 8170 adults from 27 rural and 27 urban communities and 5559 (81·4%, 80·4–82·3) of 6832 blood donors. HBsAg was detected in 495 (8·8%, 7·9–9·7) individuals in communities and 721 (13·0%, 12·1–13·9) blood donors. Prevalence was higher in men (239 [10·5%, 8·9–12·1] of 2328 men vs 256 [7·6%, 6·5–8·7] of 3652 women; p=0·004) and middle-aged participants. Linkage to care was high in the communities, with 402 (81·3%) of 495 HBsAg-positive individuals attending the clinic. However, only 300 (41·6%) of 721 HBsAg-positive people screened at the blood bank linked into care. Of those who attended the clinic, 18 (4·4%, 2·5–7·7) patients from the communities and 29 (9·7%, 6·8–13·6) from the blood bank were eligible for treatment. Male sex was strongly associated with treatment eligibility (odds ratio 4·35, 1·50–12·58; p=0·007).InterpretationHBV infection remains highly prevalent in The Gambia. The high coverage of community-based screening, good linkage into care, and the small proportion of HBsAg carriers who need treatment suggest that large-scale screening and treatment programmes are feasible in sub-Saharan Africa.FundingEuropean Commission (FP7). Despite the introduction of immunisation for hepatitis B virus (HBV) in the 1990s, HBV-related morbidity and mortality remain high in sub-Saharan Africa. Identification and treatment of asymptomatic people with chronic HBV infection should reduce the disease burden. We therefore assessed the feasibility of a screen-and-treat programme for HBV infection in The Gambia, west Africa, and estimated the proportion of HBV-infected people who had significant liver disease in need of treatment. Between Dec 7, 2011, and Jan 24, 2014, individuals living in randomly selected communities in western Gambia were offered hepatitis B surface antigen (HBsAg) screening via a point-of-care test. The test was also offered to potential blood donors attending the central hospital in the capital, Banjul. HBsAg-positive individuals were invited for a comprehensive liver assessment and were offered treatment according to international guidelines. We defined linkage to care as visiting the liver clinic at least once. Eligibility for treatment was judged in accordance with the 2012 European Association for the Study of the Liver guidelines. HBsAg screening was accepted by 5980 (weighted estimate 68·9%, 95% CI 65·0–72·4) of 8170 adults from 27 rural and 27 urban communities and 5559 (81·4%, 80·4–82·3) of 6832 blood donors. HBsAg was detected in 495 (8·8%, 7·9–9·7) individuals in communities and 721 (13·0%, 12·1–13·9) blood donors. Prevalence was higher in men (239 [10·5%, 8·9–12·1] of 2328 men vs 256 [7·6%, 6·5–8·7] of 3652 women; p=0·004) and middle-aged participants. Linkage to care was high in the communities, with 402 (81·3%) of 495 HBsAg-positive individuals attending the clinic. However, only 300 (41·6%) of 721 HBsAg-positive people screened at the blood bank linked into care. Of those who attended the clinic, 18 (4·4%, 2·5–7·7) patients from the communities and 29 (9·7%, 6·8–13·6) from the blood bank were eligible for treatment. Male sex was strongly associated with treatment eligibility (odds ratio 4·35, 1·50–12·58; p=0·007). HBV infection remains highly prevalent in The Gambia. The high coverage of community-based screening, good linkage into care, and the small proportion of HBsAg carriers who need treatment suggest that large-scale screening and treatment programmes are feasible in sub-Saharan Africa." @default.
• W2475385134 created "2016-08-23" @default.
• W2475385134 creator A5010571277 @default.
• W2475385134 creator A5017208288 @default.
• W2475385134 creator A5019539147 @default.
• W2475385134 creator A5022575375 @default.
• W2475385134 creator A5023606749 @default.
• W2475385134 creator A5026835706 @default.
• W2475385134 creator A5031576158 @default.
• W2475385134 creator A5032374292 @default.
• W2475385134 creator A5033754121 @default.
• W2475385134 creator A5033814981 @default.
• W2475385134 creator A5036957434 @default.
• W2475385134 creator A5038842430 @default.
• W2475385134 creator A5042429747 @default.
• W2475385134 creator A5050682834 @default.
• W2475385134 creator A5051872800 @default.
• W2475385134 creator A5058008551 @default.
• W2475385134 creator A5065171938 @default.
• W2475385134 creator A5067169017 @default.
• W2475385134 creator A5067192172 @default.
• W2475385134 creator A5077135288 @default.
• W2475385134 creator A5081996617 @default.
• W2475385134 creator A5085273356 @default.
• W2475385134 creator A5087084918 @default.
• W2475385134 creator A5087123292 @default.
• W2475385134 creator A5087324849 @default.
• W2475385134 creator A5089236726 @default.
• W2475385134 creator A5091339856 @default.
• W2475385134 creator A5091453833 @default.
• W2475385134 date "2016-08-01" @default.
• W2475385134 modified "2023-10-10" @default.
• W2475385134 title "Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study" @default.
• W2475385134 cites W1799522345 @default.
• W2475385134 cites W1850144958 @default.
• W2475385134 cites W1931521103 @default.
• W2475385134 cites W1942896185 @default.
• W2475385134 cites W1970884078 @default.
• W2475385134 cites W2019159968 @default.
• W2475385134 cites W2021264347 @default.
• W2475385134 cites W2031756259 @default.
• W2475385134 cites W2041626675 @default.
• W2475385134 cites W2056689920 @default.
• W2475385134 cites W2070117407 @default.
• W2475385134 cites W2081764223 @default.
• W2475385134 cites W2089437812 @default.
• W2475385134 cites W2093904708 @default.
• W2475385134 cites W2100049335 @default.
• W2475385134 cites W2112195292 @default.
• W2475385134 cites W2142181526 @default.
• W2475385134 cites W2144022511 @default.
• W2475385134 cites W2146966193 @default.
• W2475385134 cites W2149473605 @default.
• W2475385134 cites W2159672058 @default.
• W2475385134 cites W2161579655 @default.
• W2475385134 cites W2164896934 @default.
• W2475385134 cites W2261427425 @default.
• W2475385134 cites W2264031755 @default.
• W2475385134 cites W2471570375 @default.
• W2475385134 cites W2488426658 @default.
• W2475385134 cites W4211026375 @default.
• W2475385134 doi "https://doi.org/10.1016/s2214-109x(16)30130-9" @default.
• W2475385134 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27443781" @default.
• W2475385134 hasPublicationYear "2016" @default.
• W2475385134 type Work @default.
• W2475385134 sameAs 2475385134 @default.
• W2475385134 citedByCount "125" @default.
• W2475385134 countsByYear W24753851342016 @default.
• W2475385134 countsByYear W24753851342017 @default.
• W2475385134 countsByYear W24753851342018 @default.
• W2475385134 countsByYear W24753851342019 @default.
• W2475385134 countsByYear W24753851342020 @default.
• W2475385134 countsByYear W24753851342021 @default.
• W2475385134 countsByYear W24753851342022 @default.
• W2475385134 countsByYear W24753851342023 @default.
• W2475385134 crossrefType "journal-article" @default.
• W2475385134 hasAuthorship W2475385134A5010571277 @default.
• W2475385134 hasAuthorship W2475385134A5017208288 @default.
• W2475385134 hasAuthorship W2475385134A5019539147 @default.
• W2475385134 hasAuthorship W2475385134A5022575375 @default.
• W2475385134 hasAuthorship W2475385134A5023606749 @default.
• W2475385134 hasAuthorship W2475385134A5026835706 @default.
• W2475385134 hasAuthorship W2475385134A5031576158 @default.
• W2475385134 hasAuthorship W2475385134A5032374292 @default.
• W2475385134 hasAuthorship W2475385134A5033754121 @default.
• W2475385134 hasAuthorship W2475385134A5033814981 @default.
• W2475385134 hasAuthorship W2475385134A5036957434 @default.
• W2475385134 hasAuthorship W2475385134A5038842430 @default.
• W2475385134 hasAuthorship W2475385134A5042429747 @default.
• W2475385134 hasAuthorship W2475385134A5050682834 @default.
• W2475385134 hasAuthorship W2475385134A5051872800 @default.
• W2475385134 hasAuthorship W2475385134A5058008551 @default.
• W2475385134 hasAuthorship W2475385134A5065171938 @default.
• W2475385134 hasAuthorship W2475385134A5067169017 @default.
• W2475385134 hasAuthorship W2475385134A5067192172 @default.
• W2475385134 hasAuthorship W2475385134A5077135288 @default.
• W2475385134 hasAuthorship W2475385134A5081996617 @default.
• W2475385134 hasAuthorship W2475385134A5085273356 @default.

• next